










The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 
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Individuals with chronic conditions represent a high healthcare cost group and understanding 
the cost variation among individuals is important for developing appropriate policy.  This 
study aimed to investigate the sources of variation in the cost of healthcare for a cohort of 




A longitudinal observational study of asthma-related healthcare costs in a cohort of people 
with asthma (n=252). Participants were followed for three years using six-monthly postal 
surveys and individual administrative data.  The factors associated with health system and 
patient out-of-pocket costs were investigated using generalised linear mixed models. 
 
Results 
There was substantial variability around the average costs of healthcare for asthma which 
were associated with asthma-related health measures and socio-demographic variables. The 
health system costs were less for those living in regional areas relative to Sydney residents 
and both the health system and patient out-of-pocket costs were highest in the oldest age 
group and lowest for children.  The health system and patient out-of-pocket costs were highest 
for the high income group while the middle income group had the lowest total cost. 
 
Conclusions 
Our findings suggest that variations should be explored in developing strategies for chronic 
disease management and that Australia has achieved reasonable equity in access.  However, 
out-of-pocket costs may be a deterrent for the middle income group, which should be a 
general concern for policies targeting the most disadvantaged group to the exclusion of 
concern with universal access. 
Introduction 
 
The management of chronic disease is a crucial issue as healthcare systems face the challenge 
of improving health outcomes and controlling expenditure.  While individuals with chronic 
conditions represent a high healthcare cost group, little is known about the variation of costs 
and utilisation of services among individuals with the same chronic condition.  Understanding 
whether these high costs are due to uniformly high use of services, occasional acute 
episodes/exacerbations, or poor management and compliance is important in developing 
appropriate policy.  For example, research has shown that higher drug co-payments, while 
reducing short run expenditure, are associated with poorer compliance and increased 
emergency department use and hospitalisation (1, 2). 
 
Asthma is a chronic disease where good control of the condition has been shown to reduce 
costs and improve health outcomes.(3-5)  However, many people with asthma do not use 
treatment appropriately or achieve optimal asthma control;(6-9) and this may be related to the 
cost of medication and medical visits.(10, 11)  Asthma is a good case study to investigate 
variation and the effects of out-of-pocket payments in Australia.  While there have been 
substantial improvements in asthma management as evidenced by declining mortality and 
hospitalisation, acute asthma remains a major reason for presentation to a hospital emergency 
department.(6)  Although Australia’s Pharmaceutical Benefits Scheme provides universal 
access to subsidised drugs, the costs can become substantial when medications must be used 
continuously.  One study found that individuals presenting for acute asthma were likely to 
have reduced their use of preventive medication due to cost.(10)  Another showed that 
individuals who face lower co-payments for prescription drugs use more inhaled 
corticosteroids (ICS).(7)  The same study also showed that people living in remote areas use 
less asthma medication than people living in cities. 
 
The aim of this paper is to describe the variation in the cost of healthcare for a cohort of 
Australians with asthma, and to identify the sources of variation between and within 
individuals over time.  It examines the costs to the health system and the patient out-of-pocket 
costs, as well as the extent to which this variation is associated with individual socio-
economic characteristics and health status. 




A longitudinal observational study of asthma-related healthcare costs and utilisation was 
conducted in New South Wales (NSW), Australia between 2002 and 2005. The study 
recruited a random community sample of 274 people with asthma by telephone, stratified by 
age, sex and residential area (response rate 25%).  A further sample of 60 recent hospital 
emergency department attendees for asthma was included to ensure sufficient numbers with 
severe asthma (response rate 11%).  Participants were followed for three years using six-
monthly postal surveys and individual administrative data.  The recruitment and data 
collection methods have been described in detail previously.(12) The current paper reports 
data from the 252 (community sample 211, hospital sample 41) participants who completed 
two or more surveys and consented to the use of their individual administrative data from 
Medicare Australia and the NSW Health Department Inpatient Statistics Collection (ISC). 
 
Utilisation and cost measurement 
The study measured the utilisation of health services and products for asthma and then 
calculated the cost to the health system and the out-of-pocket cost to each patient over each 
six-month survey period in which they participated.  The utilisation components included: 
emergency department and inpatient hospital care, out-of-hospital medical visits and 




Hospital utilisation included admitted episodes and non-admitted emergency department (ED) 
attendances which were identified from the survey data. Individual self-reported admitted 
episodes were identified in the ISC database to obtain the diagnoses related group (DRG) 
code for the episode.  Of 117 episodes reported, 62 were not identified on the database and 
were assigned the age appropriate ‘bronchitis and asthma without complication or co-
morbidity’ DRG code.  The cost to the health system for each inpatient episode was assigned 
according to the DRG and the year of the episode.  The National Hospital Cost Data 
Collection (NHCDC) public sector cost weights(13-16) were used for all public hospital 
episodes.  Private hospital episodes were assigned the NHCDC private sector cost weights(13, 
14) for episodes before July 2003 and the Private Hospital Data Bureau (PHDB) charge 
weights(17, 18) for episodes during and after July 2003.  The Medicare benefit paid for in-
hospital medical services was included in the health system cost for inpatient hospital care for 
private hospital episodes.  The health system cost for non-admitted ED visits was calculated 
using the national average cost for all five non-admitted triage categories for all diagnoses 
from the NHCDC Cost Report relevant to the year of the episode.(13-16)  Patient out-of-
pocket costs for hospital care were calculated by combining survey reported hospital costs and 
the Medicare data for in-hospital medical services (charge minus benefit) less the private 
health insurance rebates reported in the patient surveys. 
 
Out-of-hospital medical services 
The asthma-related utilisation and cost of visits to general practitioners (GP) and specialists, 
and diagnostic tests were estimated from the Medicare data.  The health system cost was the 
Medicare benefit paid and the patient cost was the difference between the benefit and the 
charge.  The proportion of all GP visits that were asthma-related was estimated from an 
additional survey completed by a sub-sample (n=135) which found that, on average 33% of 
GP visits were asthma-related.  Thus, for each six-month survey period, 33% of the health  
Table 1: Sources of resource utilisation and cost data and associated timeframes 
Source of item cost  Item  Time period covered by data Source of utilisation data 









PBS data for six-month 
period prior to survey date 
























Surveys – in past six months 
Surveys – in past six months 
NSW Health inpatient data 
for six-month period prior to 
survey date 




Survey data and DRG for 
episode from NSW 
inpatient data 
 
Medicare data (in hospital) 
 
National hospital cost data 
National private or public 
hospital DRG costs for 
relevant year 
 







Medicare data (in hospital) 
Medical services out of 
hospital 
Medicare data for six-month 
period prior to survey date 
Medicare data
c  Medicare data  Medicare data 
Diagnostic tests  Medicare data for six-month 
period prior to survey date 
Medicare data
c  Medicare data  Medicare data 
Asthma equipment  Surveys – in past six months  Surveys  Nil  Surveys 
a The PBS data were not expected to capture the major portion of usage where: 1) the drug cost less than the PBS general patient co-payment, 2) the drug could be purchased 
with or without a prescription, 3) the drug was not listed on the PBS for the full period of the study, 4) the drug was listed for restricted use only. 
b Public hospital DRG costs included medical services but private hospital DRG costs did not. 
c Proportion of GP visits, selected specialists and selected diagnostic tests as described in text.
  
system and patient costs of each participant’s GP visits were included.  The specialist 
visits which were asthma-related were identified by the type of specialists who 
commonly have a role in managing asthma.  These included: specialists in general, 
paediatric and thoracic medicine as well as immunologists and ear, nose and throat 
specialists.  It was deemed likely that a person with asthma would visit these specialists 
for asthma-related conditions and only visits to these specialists were included.  
Similarly, specific diagnostic tests which were expected to be asthma-related were 
counted as such.  These included: allergy tests and respiratory tests (respiratory function, 
chest x-ray and sputum microscopy & culture). 
 
Pharmaceuticals and equipment 
The utilisation and cost of asthma drugs were identified from survey data and individual 
Pharmaceutical Benefits Scheme (PBS) data from Medicare Australia.  The PBS benefit 
was used to calculate the cost to the health system for prescription medicines, while the 
patient out-of-pocket cost was calculated as the gross price of the prescription less the 
PBS benefit.  The survey data were used to calculate patient out-of-pocket costs where 
there was reason to believe that the PBS data would not capture the major portion of 
usage.  These included: short-acting beta agonists (SABA), leukotreine receptor 
antagonists and oral cortico-steroids (OCS).  Most SABA & OCS items cost less than the 
PBS general patient co-payment and would only attract a PBS benefit (and therefore 
appear in the data) for concession cardholders or for general patients when they become 
eligible for the safety-net (which applies for the remainder of the calendar year after the 
qualifying level of personal health expenditure is reached).  SABA would also not appear 
in the PBS data when purchased without a prescription.  The leukotreine receptor 
antagonist, montelukast, was added to the PBS during the study and had restrictions on its 
use.  Consequently, the PBS data would not capture usage by those who used it prior to 
the PBS listing or by those who do not satisfy the PBS restrictions.  Survey data were 
used to estimate the out-of-pocket costs for all non-prescription medicines used for 
asthma and for equipment such as spacers and nebulisers. 
 
Asthma-related health measures 
All asthma-related health measures were collected in the six-monthly surveys. These 
included questions about activity limitations due to asthma in the past 6 months (3 items), 
sleep disturbance due to asthma in the past 4 weeks (1 item), SABA use in the past 4 
weeks (2 items) and urgent medical visits for an asthma attack in the past 4 weeks (1 
item). The three activity limitations items were combined to produce a score between 0 
(no limitation) and 4 (extremely limited) which has been described elsewhere.(19)  The 
two SABA use items (the number of days used in the past 4 weeks and the number of 
times on those days) were used to calculate the average number of times per day in the 
past 4 weeks.(19)  The survey also included questions about the use and frequency of 
preventive medications to treat asthma in the past 4 weeks.  Participants were classified 
as using asthma treatment if they reported using these medicines on most or all days.  
Asthma treatment was classified as either inhaled corticosteroids (ICS) alone or 
combined ICS and long-acting beta agonists (LABA), regardless of whether ICS and 
LABA were used as one or two drugs. 
 
Statistical analysis 
Data from the hospital and community samples were combined for all analyses. The costs 
to the health system and patient out-of-pocket costs were analysed separately. The factors 
  
associated with each cost type were investigated using generalised linear mixed 
models.(20) Two-part models (21, 22) were used because the distribution of each cost 
variable was highly skewed with substantial numbers of zero observations (10-20%) and 
a long right tail (Table 2).  The first part modelled the probability of a positive cost using 
a binomial distribution function with a logit link, while the second part modelled the 
expected cost conditional on a positive cost using a gamma distribution function with a 
log link.  Because of the repeated measures nature of the data, the models included a 
random person-specific intercept for each part of the two-part model and the covariance 
of the two random parameters. 
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for j=1 to 5 observations (surveys 2 to 6), i=1 to N individuals and k=1 to K covariates.  
The α’s and β’s are the regression parameters for part 1 and part 2 respectively. δi1 is the 
random intercept term for part 1 (the random person effect for the occurrence of cost) and 
 is the associated variance. δi2 is the random intercept term for part 2 (the random 
person effect for the magnitude of cost conditional on a positive cost) and   is the 





σ σ  is the covariance of the two random intercepts.  Estimation 
was by residual pseudo-likelihood using SAS Proc Glimmix (23) and t-tests were used to 
test the significance of fixed effects. 
 
Table 2: Study response
* and distribution of six-monthly costs
† over time 
  Data collection wave 















Cost to the health system 
Mean  457 461 402 388 596 379 
Standard  deviation  1,429 1,664 1,176 1,055 1,993 1,190 
Minimum  0 0 0 0 0 0 
Maximum 14,008 16,185 12,220 11,591 15,675 13,126 
Median  71 84 75 89 106  100 
%  =  zero  11 10 12 11 10 12 
Cost to patients 
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Mean  78 84 82 77 113  117 
Standard  deviation  145 148 174 139 500 406 
Minimum  0 0 0 0 0 0 
Maximum  1,426 1,824 2,186 1,428 6,775 5,045 
Median  39 48 40 40 41 31 
%  =  zero  12 12 12 14 11 20 
* Subjects with all data sources available at each 6-monthly survey period 
† 2002 Australian dollars 
 
The models aimed to identify the socio-demographic characteristics and self-reported 
asthma-related health measures associated with asthma-related costs to the health system 
and to patients. Costs from survey periods 2 to 6 were modelled as a function of hospital 
admissions at period 1, time varying health measures (asthma-related activity limitations 
and sleep disturbance in periods 2 to 6) and the baseline socio-demographic variables, 
sex, age group, residential area (capital city or regional), private health insurance (PHI) 
and gross household income group.  The same covariates were included in both models 
(costs to the health system and patient out-of-pocket costs) and in both parts of each 
model (logistic or gamma). 
 
The predicted mean cost for the whole sample was calculated as the conditional expected 
cost from the gamma part of the model times the probability of a positive cost from the 
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This was calculated using simulation which took 1000 random draws from the estimated 
distributions of the logistic part and gamma part random intercepts, with the expected 
cost estimated for each draw.  The reported expected cost is the mean of the 1000 
replications. 
 
To identify if the same individuals consistently had high or low costs (within-person 
variation), we calculated the maximum within-person difference for each individual as 
the difference between the most expensive and least expensive time-points for health 
system and out-of-pocket costs.
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Results 
 
The characteristics of the sample at recruitment to the study are reported in Table 3. More 
than half of the sample reported the regular use of ICS (either alone or in combination 
with LABA).  While on average respondents reported using SABA more than once daily 
in the past month, 22% reported no use.  Less than half (44%) reported asthma-related 
sleep disturbance in the past month, while few reported urgent medical visits or 
hospitalisation.  The majority (75%) reported activity limitation due to asthma in the past 
6 months, but on average the activity limitation score indicated only a little limitation. 
 
Table 3: Characteristics of the sample at recruitment to the study (n=252) 
 % Mean  (sd) 
Hospital recruitment  16  



















Private health insurance for hospital  49  










Activity limitation due to asthma 
(past 6 months, 0-4)
* 
0.9 (0.9) 
Sleep disturbance due to asthma 
(past month, nights/week) 
0.8 (1.5) 
Short-acting beta agonist use 
(past month, times/day) 
1.3 (1.5) 
Urgent medical visit due to asthma 
(past month) 
14  
Hospital admission due to asthma 
(past 6 months) 
6 
Current asthma treatment: 
Inhaled corticosteroid & long-acting beta agonist 




*0=no limitation, 4=Extremely limited 
 
The survey response rate declined over the follow-up period; of the 252 respondents with 
administrative data and at least two surveys, 168 (67%) responded to all six surveys 
(Table 1).  Age was the only characteristic where respondents with complete follow-up 
and those with partial follow-up differed significantly (χ
2=13.30, df=4, p=0.010); the 11-
17 years age group had the lowest rate of complete data (44%) and the 60-75 years age 
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group had the highest (76%).  Over the follow-up period (time-points 2 to 6), the 252 
respondents provided a total of 1,036 observations (each covering six months of resource 
use). 
 
Costs to the health system for asthma 
The average cost to the health system was $457 (standard deviation 1,429; range 0 to 
14,008) in the first six months and $445 per six months (standard deviation 1,462; range 
0 to 16,185) over the remainder of the study (time-points 2 to 6).  The majority of 
individuals showing relatively small within-person changes over time; for 75% of the 
sample, the maximum within-person difference was $361 or less (Table 4).  The model 
explained 29% of the variance between individuals in the probability of having a cost and 
45% of the variance in the amount of the cost when there was a cost. 
 
Table 4: Maximum within-person difference
* in health system and out-of-pocket costs for 
individuals over 6 data collection waves 








Mean (standard deviation)  658 (1768) 144 (434)
Maximum 13,924 6,444
90
th percentile  1704 270
75
th percentile  361 132
Median 155 68
25
th percentile  62 30
10
th percentile  22 10
Minimum 0 0
*Cost at the most expensive time-point minus the cost at the least expensive time-point. 
† 2002 Australian dollars. 
 
Two of the three asthma-related health measures were significantly associated with costs 
to the health system.  As the level of asthma-related activity limitation increased so did 
both the probability of a cost and the amount of the cost, while those with an asthma-
related hospital admission within the first six months (time-point 1) had higher costs in 
the subsequent periods than those with no admission at time-point 1 (Table 5).  Age was 
associated with both the probability of a cost and the amount of the cost; while residential 
area was associated with the amount of the cost, but not the probability of a cost (Table 
5).  The average six-monthly cost to the health system was highest for the oldest age 
group (60-75 years); it was $348 less for the next age group (40-59 years) and $460 to 
$500 less for the three youngest age groups (5-10, 11-17 and 18-39 years, Table 6).  
Average costs to the health system were lower for Regional NSW residents than for 
Sydney residents. 
 
Gross household income was significantly associated with the probability of a cost to the 
health system but not the amount of the cost; the middle income group ($700-1499 per 
week) had a significantly lower probability of a cost than either the high ($1500 or more 
per week) or low ($699 or less per week) groups (Table 5).  The average six-monthly cost 
to the health system was $51 to $187 more for the high income group than for the middle 
group (Table 6). PHI was associated with the amount of the cost but not the probability of 
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a cost; the average six-monthly cost to the health system for those with PHI was $37 to 
$200 less than for those without PHI. 
 
Table 5: Asthma costs per 6 month survey period (surveys 2 to 6): model coefficients and 
standard errors from a two-part binomial logit and gamma log model (n=252). 
  Health system  Patient out-of-pocket 






***  1.14 2.04
*** 0.56 
Asthma-related health measures 
Activity limitations
†  0.94
*** 0.26  0.50
* 0.20 
Sleep disturbance
† 0.08  0.17  0.10  0.12 
Admission survey 1  -0.50  0.58  0.61  0.65 
Socio-demographic covariates 
Male -0.48  0.27  0.01  0.27 
Age 
05-10  -4.08
*** 1.04  -0.89
* 0.39 
11-17 -4.21
*** 1.05  -0.88
* 0.42 
18-39 -3.37
** 1.06  -0.12 0.45 
40-59 -2.98
** 1.05 0.34 0.44 
60-75  Reference   Reference  
Residential area 
Regional NSW  -0.33 0.26  0.65
* 0.27 
Sydney metropolitan  Reference    Reference   
Private health insurance  -0.05  0.27  0.64
* 0.28 
Income (gross household) 
Missing -1.23
* 0.53  -0.50 0.53 
$1-699 pw  -0.80  0.47  -0.61  0.44 
$700-1499 pw  -1.42
** 0.45  -0.94
* 0.43 
$1500 or more pw  Reference    Reference   
Gamma model 
Intercept 5.91
*** 0.28  4.19
*** 0.25 
Asthma-related health measures 
Activity limitations
†  0.38
*** 0.05  0.29
*** 0.04 
Sleep disturbance
† 0.03  0.02  0.06
** 0.02 
Admission survey 1  1.75
*** 0.29  0.68
** 0.25 
Socio-demographic covariates 
Male -0.12  0.14  -0.12  0.13 
Age 
05-10  -1.57
*** 0.22  -0.43
* 0.19 
11-17 -1.41
*** 0.23  -0.09 0.21 
18-39 -1.39
*** 0.22  -0.09 0.20 
40-59 -0.81
*** 0.20 0.02 0.18 
60-75  Reference   Reference  
Residential area 
Regional NSW  -0.40
** 0.14  -0.14 0.13 
Sydney metropolitan  Reference    Reference   
Private health insurance  -0.40
** 0.15 0.00 0.13 
Income (gross household) 
Missing -0.27  0.26  -0.42  0.23 
$1-699 pw  -0.08  0.22  -0.61
** 0.19 
$700-1499 pw  -0.36  0.22  -0.22  0.19 
$1500 or more pw  Reference    Reference   
Random effects 
Binomial model intercept variance  0.64  0.20  1.10  0.23 
Gamma model intercept variance  1.00  0.12  0.76  0.08 
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Covariance 0.73  0.15  0.53  0.13 
Residual 0.45  0.02  0.34  0.02 
*p<0.05; **p<0.01; ***p<0.001. 
† Time varying variable. 
 
Table 6: Expected six-monthly costs
* for asthma (selected sub-groups
**) 





Age $1-699  $700-1499  >=$1500  Yes No Yes  No
Health system costs 
05-10 94 62 113 612 113 76  113
11-17 107  70 131 701 131 87  131
18-39 124  86 143 790 143 95  143
40-59 230 163 261 1458 261 175  261
60-75 561 422 609 3483 609 409  609
Patient out-of-pocket costs 
05-10 21 27 45 101 45 51  45
11-17 29 38 64 142 64 73  64
18-39 36 49 74 157 74 80  74
40-59 44 61 87 181 87 92  87
60-75 40 55 82 173 82 88  82
*2002 Australian dollar. 
**All estimates for female Sydney residents reporting no activity limitation or sleep disturbance. 
 
Patient out-of-pocket costs for asthma 
The average out-of-pocket cost to patients was $78 (standard deviation 145; range 0 to 
1426) in the first six months and $93 per six months (standard deviation 296; range 0 to 
6775) over the remainder of the study (time-points 2 to 6). The majority of individuals 
showed relatively small changes over time; for 75% of the sample, the maximum within-
person difference was $132 or less (Table 4). The models explained 15% of the variance 
between individuals in the probability of having a cost and 20% of the variance in the 
amount of the cost when there was a cost. 
 
All three asthma-related health measures were significantly associated with costs to 
patients.  As the level of asthma-related activity limitation increased so did both the 
probability of a cost and the amount of the cost, while an increase in asthma-related sleep 
disturbance was associated with an increase in the amount of the cost but not the 
probability of a cost.  Those with an asthma-related hospital admission at time-point 1 
had higher costs in the subsequent periods than those with no admission at time-point 1 
(Table 5).  Age was associated with both the probability of a cost and the amount of the 
cost; while residential area was associated with the probability of a cost, but not the 
amount of the cost (Table 5).  Expected six-monthly costs to patient were $11 to $42 
lower for children than for the two oldest age groups (40-59 and 60-75 years, Table 6).  
Regional NSW residents had a higher probability of an out-of-pocket cost than Sydney 
residents. 
 
Gross household income was significantly associated with both the probability of a 
patient cost and the amount of the cost; the middle income group had a significantly 
lower probability of a cost than the high group and, when there was a cost, it was 
significantly lower for the low income group compared to the other groups (Table 5). For 
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the high income group, the average six-monthly patient cost was $24 to $43 more than 
for the low income group and $18 to $27 more than for the middle group (Table 6).  PHI 
was associated with the probability of a patient cost but not the amount of the cost; the 
average six-monthly cost to patients was $5 to $9 more for those with PHI relative to 
those without PHI. 
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Discussion 
 
The healthcare costs to patients and the health system costs for asthma varied between 
individuals but showed little within-person variation over time.  Thus those with more 
severe asthma-related problems remained relatively high cost users.  Not surprisingly 
healthcare costs were higher for those with evidence of poor asthma control.  Both health 
system and patient out-of-pocket costs were associated with asthma-related activity 
limitation and patient out-of-pocket costs were associated with asthma-related sleep 
disturbance.  An asthma-related admission at baseline was associated with higher health 
system and patient out-of-pocket costs at subsequent time-points and had the largest 
effect on costs. 
 
Some of the variation in cost was explained by socio-economic and demographic 
characteristics.  Older people used more resources and incurred higher out-of-pocket 
costs, consistent with other Australian research.(6)  Other variables associated with costs 
were area of residence, PHI and household income.  Costs to the health system were less 
for those living in Regional NSW compared to Sydney residents and for those with PHI 
compared to those without, but out-of-pocket costs were similar.  The high income group 
cost the health system more than the middle or low income groups and incurred higher 
out-of-pocket costs. 
 
Average patient out-of-pocket costs were not large and were similar across all income 
groups. While these were highest for the high income group, they may impose a greater 
burden for the low and middle income groups.  The model explained only a small portion 
of the variance, indicating that this was largely driven by unmeasured factors.  Overall, 
these costs were highly skewed with the majority having a relatively low cost and a 
minority having high expenditure which was predominantly for medication. 
 
Perhaps more surprising is the finding that income related variation in health sector borne 
costs persists after adjusting for age and health.  Costs were higher for both the low and 
high income groups relative to the middle group.  Most of the low income group are 
entitled to lower co-payments for medication and may be more likely to receive general 
practitioner services without additional user charges.  This lower utilisation by the middle 
income group may be related to co-payments, which would be consistent with other 
research.(7, 10) 
 
These results should be interpreted with caution as the causal direction of associations 
can be difficult to determine in an observational study.  Also, the data collection did not 
include physical measures of asthma status and many measures such as urgent medical 
visits, are linked to resource use so were not suitable for this study.  Response rates were 
low, particularly in the most mobile group of young adults, and while the sample may not 
be representative of all NSW people with asthma, non-responders were similar to 
responders on most measured characteristics.(12)  Nonetheless, this study does comprise 
people with a wide range of asthma severity and sufficient numbers in sub-groups to 
detect differences, which was the aim of the study. 
 
Our findings show that there is substantial variation in the costs and health care utilisation 
within this group of people with a chronic condition; and that many high users remain a 
high cost to the health system.  While the experience of asthma may not be generalisable 
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to all other chronic conditions, it does suggest that variations should be explored in 
developing strategies for chronic disease management.  The findings suggest a reasonable 
achievement of equity in access and that high out-of-pocket costs are not widespread.  
There is pro-poor bias in that the low income group did not incur significantly lower 
service use than the high income group.  However, the middle income group did use 
fewer services and this may suggest that out-of-pocket costs are a deterrent in this group, 
who are also expected to meet higher co-payments.  This should be a general concern for 
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